Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer.

Mirlekar B, Michaud D, Searcy R, Greene K, Pylayeva-Gupta Y.

Cancer Immunol Res. 2018 Sep;6(9):1014-1024. doi: 10.1158/2326-6066.CIR-17-0710. Epub 2018 Jul 6.

PMID:
29980536
2.

Molecular Pathways: Interleukin-35 in Autoimmunity and Cancer.

Pylayeva-Gupta Y.

Clin Cancer Res. 2016 Oct 15;22(20):4973-4978. Epub 2016 Aug 31. Review.

3.

KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment.

Zeitouni D, Pylayeva-Gupta Y, Der CJ, Bryant KL.

Cancers (Basel). 2016 Apr 18;8(4). pii: E45. doi: 10.3390/cancers8040045. Review.

4.

IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia.

Pylayeva-Gupta Y, Das S, Handler JS, Hajdu CH, Coffre M, Koralov SB, Bar-Sagi D.

Cancer Discov. 2016 Mar;6(3):247-55. doi: 10.1158/2159-8290.CD-15-0843. Epub 2015 Dec 29.

5.

Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.

Grabocka E, Pylayeva-Gupta Y, Jones MJ, Lubkov V, Yemanaberhan E, Taylor L, Jeng HH, Bar-Sagi D.

Cancer Cell. 2014 Feb 10;25(2):243-56. doi: 10.1016/j.ccr.2014.01.005.

6.

Microdissection and culture of murine pancreatic ductal epithelial cells.

Pylayeva-Gupta Y, Lee KE, Bar-Sagi D.

Methods Mol Biol. 2013;980:267-79. doi: 10.1007/978-1-62703-287-2_14.

PMID:
23359159
7.

MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells.

Ochi A, Nguyen AH, Bedrosian AS, Mushlin HM, Zarbakhsh S, Barilla R, Zambirinis CP, Fallon NC, Rehman A, Pylayeva-Gupta Y, Badar S, Hajdu CH, Frey AB, Bar-Sagi D, Miller G.

J Exp Med. 2012 Aug 27;209(9):1671-87. doi: 10.1084/jem.20111706. Epub 2012 Aug 20.

8.

Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia.

Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G, Bar-Sagi D.

Cancer Cell. 2012 Jun 12;21(6):836-47. doi: 10.1016/j.ccr.2012.04.024.

9.

Silencing the killers: paracrine immune suppression in pancreatic cancer.

Cox AD, Olive KP.

Cancer Cell. 2012 Jun 12;21(6):715-6. doi: 10.1016/j.ccr.2012.05.029.

10.

EZH2 couples pancreatic regeneration to neoplastic progression.

Mallen-St Clair J, Soydaner-Azeloglu R, Lee KE, Taylor L, Livanos A, Pylayeva-Gupta Y, Miller G, Margueron R, Reinberg D, Bar-Sagi D.

Genes Dev. 2012 Mar 1;26(5):439-44. doi: 10.1101/gad.181800.111.

11.

RAS oncogenes: weaving a tumorigenic web.

Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D.

Nat Rev Cancer. 2011 Oct 13;11(11):761-74. doi: 10.1038/nrc3106. Review.

12.

Molecular characterization of the tumor-suppressive function of nischarin in breast cancer.

Baranwal S, Wang Y, Rathinam R, Lee J, Jin L, McGoey R, Pylayeva Y, Giancotti F, Blobe GC, Alahari SK.

J Natl Cancer Inst. 2011 Oct 19;103(20):1513-28. doi: 10.1093/jnci/djr350. Epub 2011 Sep 14.

13.

Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling.

Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF, Giancotti FG.

J Clin Invest. 2009 Feb;119(2):252-66. doi: 10.1172/JCI37160. Epub 2009 Jan 19.

14.

Analysis of integrin signaling in genetically engineered mouse models of mammary tumor progression.

Pylayeva Y, Guo W, Giancotti FG.

Methods Enzymol. 2007;426:439-61. Review.

PMID:
17697895
15.

Tensin relief facilitates migration.

Pylayeva Y, Giancotti FG.

Nat Cell Biol. 2007 Aug;9(8):877-9. No abstract available.

PMID:
17671456
16.

Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis.

Guo W, Pylayeva Y, Pepe A, Yoshioka T, Muller WJ, Inghirami G, Giancotti FG.

Cell. 2006 Aug 11;126(3):489-502.

17.

Development requires activation but not phosphorylation of beta1 integrins.

Pylayeva Y, Giancotti FG.

Genes Dev. 2006 May 1;20(9):1057-60. No abstract available.

Supplemental Content

Loading ...
Support Center